In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Innovation Clinical Trials Research & Development

BioInvent Using New Screening Platforms To Identify Novel IO Targets

Biotech Boasts Five Compounds Being Examined Across Six Studies

  • Analysis

Executive Summary

Swedish biotech BioInvent uses its extensive antibody library to identify new immuno-oncology targets and translate these into therapies. Following the delivery of some impressive early-stage research at the annual Society for Immunotherapy for Cancer conference, CEO Martin Welschof caught up with In Vivo to share more about the firm’s story so far.

Table

View full table

Topics

Related Companies

Tags:
Innovation Clinical Trials Research & Development
Latest Headlines

Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics

Fujifilm Demonstrates Health Specialism With European HealthTech Spinout

Financing Quarterly Statistics, Q1 2024

Helping Organizations Deliver On KPIs And Giving Staff A Voice

See All
UsernamePublicRestriction

Register

IV148652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By